NT5C2 germline variants alter thiopurine metabolism and are associated with acquired NT5C2 relapse mutations in childhood acute lymphoblastic leukaemia

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

NT5C2 germline variants alter thiopurine metabolism and are associated with acquired NT5C2 relapse mutations in childhood acute lymphoblastic leukaemia. / Tulstrup, Morten; Grosjean, Marie; Nielsen, Stine Nygaard; Grell, Kathrine; Wolthers, Benjamin Ole; Wegener, Peder Skov; Jonsson, Olafur Gisli; Lund, Bendik; Harila-Saari, Arja; Abrahamsson, Jonas; Vaitkeviciene, Goda; Pruunsild, Kaie; Toft, Nina; Holm, Mette; Hulegårdh, Erik; Liestøl, Sigurd; Griskevicius, Laimonas; Punab, Mari; Wang, Jinhua; Carroll, William L; Zhang, Zeyu; Dalgaard, Marlene D.; Gupta, Ramneek; Nersting, Jacob; Schmiegelow, Kjeld.

I: Leukemia, Bind 32, 2018, s. 2527-2535.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Tulstrup, M, Grosjean, M, Nielsen, SN, Grell, K, Wolthers, BO, Wegener, PS, Jonsson, OG, Lund, B, Harila-Saari, A, Abrahamsson, J, Vaitkeviciene, G, Pruunsild, K, Toft, N, Holm, M, Hulegårdh, E, Liestøl, S, Griskevicius, L, Punab, M, Wang, J, Carroll, WL, Zhang, Z, Dalgaard, MD, Gupta, R, Nersting, J & Schmiegelow, K 2018, 'NT5C2 germline variants alter thiopurine metabolism and are associated with acquired NT5C2 relapse mutations in childhood acute lymphoblastic leukaemia', Leukemia, bind 32, s. 2527-2535. https://doi.org/10.1038/s41375-018-0245-3

APA

Tulstrup, M., Grosjean, M., Nielsen, S. N., Grell, K., Wolthers, B. O., Wegener, P. S., Jonsson, O. G., Lund, B., Harila-Saari, A., Abrahamsson, J., Vaitkeviciene, G., Pruunsild, K., Toft, N., Holm, M., Hulegårdh, E., Liestøl, S., Griskevicius, L., Punab, M., Wang, J., ... Schmiegelow, K. (2018). NT5C2 germline variants alter thiopurine metabolism and are associated with acquired NT5C2 relapse mutations in childhood acute lymphoblastic leukaemia. Leukemia, 32, 2527-2535. https://doi.org/10.1038/s41375-018-0245-3

Vancouver

Tulstrup M, Grosjean M, Nielsen SN, Grell K, Wolthers BO, Wegener PS o.a. NT5C2 germline variants alter thiopurine metabolism and are associated with acquired NT5C2 relapse mutations in childhood acute lymphoblastic leukaemia. Leukemia. 2018;32:2527-2535. https://doi.org/10.1038/s41375-018-0245-3

Author

Tulstrup, Morten ; Grosjean, Marie ; Nielsen, Stine Nygaard ; Grell, Kathrine ; Wolthers, Benjamin Ole ; Wegener, Peder Skov ; Jonsson, Olafur Gisli ; Lund, Bendik ; Harila-Saari, Arja ; Abrahamsson, Jonas ; Vaitkeviciene, Goda ; Pruunsild, Kaie ; Toft, Nina ; Holm, Mette ; Hulegårdh, Erik ; Liestøl, Sigurd ; Griskevicius, Laimonas ; Punab, Mari ; Wang, Jinhua ; Carroll, William L ; Zhang, Zeyu ; Dalgaard, Marlene D. ; Gupta, Ramneek ; Nersting, Jacob ; Schmiegelow, Kjeld. / NT5C2 germline variants alter thiopurine metabolism and are associated with acquired NT5C2 relapse mutations in childhood acute lymphoblastic leukaemia. I: Leukemia. 2018 ; Bind 32. s. 2527-2535.

Bibtex

@article{b5058686405444fab4a80b962a31e087,
title = "NT5C2 germline variants alter thiopurine metabolism and are associated with acquired NT5C2 relapse mutations in childhood acute lymphoblastic leukaemia",
abstract = "The antileukaemic drug 6-mercaptopurine is converted into thioguanine nucleotides (TGN) and incorporated into DNA (DNA-TG), the active end metabolite. In a series of genome-wide association studies, we analysed time-weighted means (wm) of erythrocyte concentrations of TGN (Ery-TGN) and DNA-TG in 1009 patients undergoing maintenance therapy for acute lymphoblastic leukaemia (ALL). In discovery analyses (454 patients), the propensity for DNA-TG incorporation (wmDNA-TG/wmEry-TGN ratio) was significantly associated with three intronic SNPs in NT5C2 (top hit: rs72846714; P = 2.09 × 10-10, minor allele frequency 15%). In validation analyses (555 patients), this association remained significant during both early and late maintenance therapy (P = 8.4 × 10-6 and 1.3 × 10-3, respectively). The association was mostly driven by differences in wmEry-TGN, but in regression analyses adjusted for wmEry-TGN (P < 0.0001), rs72846714-A genotype was also associated with a higher wmDNA-TG (P = 0.029). Targeted sequencing of NT5C2 did not identify any missense variants associated with rs72846714 or wmEry-TGN/wmDNA-TG. rs72846714 was not associated with relapse risk, but in a separate cohort of 180 children with relapsed ALL, rs72846714-A genotype was associated with increased occurrence of relapse-specific NT5C2 gain-of-function mutations that reduce cytosol TGN levels (P = 0.03). These observations highlight the impact of both germline and acquired mutations in drug metabolism and disease trajectory.",
author = "Morten Tulstrup and Marie Grosjean and Nielsen, {Stine Nygaard} and Kathrine Grell and Wolthers, {Benjamin Ole} and Wegener, {Peder Skov} and Jonsson, {Olafur Gisli} and Bendik Lund and Arja Harila-Saari and Jonas Abrahamsson and Goda Vaitkeviciene and Kaie Pruunsild and Nina Toft and Mette Holm and Erik Huleg{\aa}rdh and Sigurd Liest{\o}l and Laimonas Griskevicius and Mari Punab and Jinhua Wang and Carroll, {William L} and Zeyu Zhang and Dalgaard, {Marlene D.} and Ramneek Gupta and Jacob Nersting and Kjeld Schmiegelow",
year = "2018",
doi = "10.1038/s41375-018-0245-3",
language = "English",
volume = "32",
pages = "2527--2535",
journal = "Leukemia",
issn = "0887-6924",
publisher = "nature publishing group",

}

RIS

TY - JOUR

T1 - NT5C2 germline variants alter thiopurine metabolism and are associated with acquired NT5C2 relapse mutations in childhood acute lymphoblastic leukaemia

AU - Tulstrup, Morten

AU - Grosjean, Marie

AU - Nielsen, Stine Nygaard

AU - Grell, Kathrine

AU - Wolthers, Benjamin Ole

AU - Wegener, Peder Skov

AU - Jonsson, Olafur Gisli

AU - Lund, Bendik

AU - Harila-Saari, Arja

AU - Abrahamsson, Jonas

AU - Vaitkeviciene, Goda

AU - Pruunsild, Kaie

AU - Toft, Nina

AU - Holm, Mette

AU - Hulegårdh, Erik

AU - Liestøl, Sigurd

AU - Griskevicius, Laimonas

AU - Punab, Mari

AU - Wang, Jinhua

AU - Carroll, William L

AU - Zhang, Zeyu

AU - Dalgaard, Marlene D.

AU - Gupta, Ramneek

AU - Nersting, Jacob

AU - Schmiegelow, Kjeld

PY - 2018

Y1 - 2018

N2 - The antileukaemic drug 6-mercaptopurine is converted into thioguanine nucleotides (TGN) and incorporated into DNA (DNA-TG), the active end metabolite. In a series of genome-wide association studies, we analysed time-weighted means (wm) of erythrocyte concentrations of TGN (Ery-TGN) and DNA-TG in 1009 patients undergoing maintenance therapy for acute lymphoblastic leukaemia (ALL). In discovery analyses (454 patients), the propensity for DNA-TG incorporation (wmDNA-TG/wmEry-TGN ratio) was significantly associated with three intronic SNPs in NT5C2 (top hit: rs72846714; P = 2.09 × 10-10, minor allele frequency 15%). In validation analyses (555 patients), this association remained significant during both early and late maintenance therapy (P = 8.4 × 10-6 and 1.3 × 10-3, respectively). The association was mostly driven by differences in wmEry-TGN, but in regression analyses adjusted for wmEry-TGN (P < 0.0001), rs72846714-A genotype was also associated with a higher wmDNA-TG (P = 0.029). Targeted sequencing of NT5C2 did not identify any missense variants associated with rs72846714 or wmEry-TGN/wmDNA-TG. rs72846714 was not associated with relapse risk, but in a separate cohort of 180 children with relapsed ALL, rs72846714-A genotype was associated with increased occurrence of relapse-specific NT5C2 gain-of-function mutations that reduce cytosol TGN levels (P = 0.03). These observations highlight the impact of both germline and acquired mutations in drug metabolism and disease trajectory.

AB - The antileukaemic drug 6-mercaptopurine is converted into thioguanine nucleotides (TGN) and incorporated into DNA (DNA-TG), the active end metabolite. In a series of genome-wide association studies, we analysed time-weighted means (wm) of erythrocyte concentrations of TGN (Ery-TGN) and DNA-TG in 1009 patients undergoing maintenance therapy for acute lymphoblastic leukaemia (ALL). In discovery analyses (454 patients), the propensity for DNA-TG incorporation (wmDNA-TG/wmEry-TGN ratio) was significantly associated with three intronic SNPs in NT5C2 (top hit: rs72846714; P = 2.09 × 10-10, minor allele frequency 15%). In validation analyses (555 patients), this association remained significant during both early and late maintenance therapy (P = 8.4 × 10-6 and 1.3 × 10-3, respectively). The association was mostly driven by differences in wmEry-TGN, but in regression analyses adjusted for wmEry-TGN (P < 0.0001), rs72846714-A genotype was also associated with a higher wmDNA-TG (P = 0.029). Targeted sequencing of NT5C2 did not identify any missense variants associated with rs72846714 or wmEry-TGN/wmDNA-TG. rs72846714 was not associated with relapse risk, but in a separate cohort of 180 children with relapsed ALL, rs72846714-A genotype was associated with increased occurrence of relapse-specific NT5C2 gain-of-function mutations that reduce cytosol TGN levels (P = 0.03). These observations highlight the impact of both germline and acquired mutations in drug metabolism and disease trajectory.

U2 - 10.1038/s41375-018-0245-3

DO - 10.1038/s41375-018-0245-3

M3 - Journal article

C2 - 30201983

VL - 32

SP - 2527

EP - 2535

JO - Leukemia

JF - Leukemia

SN - 0887-6924

ER -

ID: 204196567